Serial 99221378
Live / Allowed — Notice of allowance issued (as of 20 Jan 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 06 Jun 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99221378
- Mark type
- Design / logo
- Filed
- 06 Jun 2025
- Published for opposition
- 25 Nov 2025
- Attorney of record
- Elizabeth K. Rucki
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders; Pharmaceutical preparations for the prevention of infectious diseases; Vaccines; Anti-infectives
Owner
- Glaxo Group Limited, Stevenage, GB
- Glaxo Group Limited, Stevenage, GB
Prosecution history
- 20 Jan 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 25 Nov 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 25 Nov 2025 — PUBLISHED FOR OPPOSITION
- 19 Nov 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 30 Oct 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 29 Oct 2025 — EXAMINER'S AMENDMENT ENTERED
- 29 Oct 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 29 Oct 2025 — EXAMINERS AMENDMENT E-MAILED
- 29 Oct 2025 — EXAMINERS AMENDMENT -WRITTEN
- 24 Oct 2025 — ASSIGNED TO EXAMINER
- 27 Jul 2025 — NOTICE OF DESIGN SEARCH CODE E-MAILED
- 27 Jul 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 06 Jun 2025 — APPLICATION FILING RECEIPT MAILED
- 06 Jun 2025 — NEW APPLICATION ENTERED